Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
1 hedge funds and large institutions have $3.62M invested in Seelos Therapeutics, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $4.52M → $3.62M (-$902K)
85% less call options, than puts
Call options by funds: $61K | Put options by funds: $404K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
-$240K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Nomura Holdings
Tokyo,
Japan
| – | -$44K | – | – |
|
|
NSIM
27
North Star Investment Management
Chicago,
Illinois
| – | -$240K | – | – |
|
SEEL Hedge Fund Activity: Q3 2013 in Review
1 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2013, worth a combined $3.62M — down 20% from $4.52M a quarter earlier.
Fund positioning in SEEL was balanced in Q3 2013: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was North Star Investment Management, cutting an estimated $240K.
- 1 institutional investor held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $3.62M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2013, down 20% quarter-over-quarter.
- 0 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2013 and 0 closed out.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2013 was North Star Investment Management, an estimated $240K sold.
Based on aggregated 13F filings for Q3 2013.